Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
NETWORK
Sponsor class

Conditions

Interventions

Sponsor

Eastern Cooperative Oncology Group

Collaborators